MX2022012073A - Metodos para el diagnostico y el tratamiento del cancer metastasico. - Google Patents

Metodos para el diagnostico y el tratamiento del cancer metastasico.

Info

Publication number
MX2022012073A
MX2022012073A MX2022012073A MX2022012073A MX2022012073A MX 2022012073 A MX2022012073 A MX 2022012073A MX 2022012073 A MX2022012073 A MX 2022012073A MX 2022012073 A MX2022012073 A MX 2022012073A MX 2022012073 A MX2022012073 A MX 2022012073A
Authority
MX
Mexico
Prior art keywords
methods
diagnosing
metastatic cancer
treating metastatic
mirna
Prior art date
Application number
MX2022012073A
Other languages
English (en)
Inventor
John Lewis
Konstantin Stoletov
Lian Willetts
Original Assignee
Entos Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entos Pharmaceuticals Inc filed Critical Entos Pharmaceuticals Inc
Publication of MX2022012073A publication Critical patent/MX2022012073A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Inorganic Chemistry (AREA)

Abstract

Se describen los métodos para diagnosticar y tratar el cáncer metastásico en un sujeto. Los métodos implican detectar o modular la expresión de al menos uno de Kif3b, ACTB, SRPK1, TMEM229b, C14orf142, KB-1460A1.5, ACTC1, Nr2f1, KIAA0922, KDELR3, APBA2, ARNmi 130b, ARNmi 374b o ARNmi 122 en una muestra biológica del sujeto.
MX2022012073A 2016-06-14 2018-12-13 Metodos para el diagnostico y el tratamiento del cancer metastasico. MX2022012073A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CA2932910A CA2932910A1 (en) 2016-06-14 2016-06-14 Methods for diagnosing and treating metastatic cancer

Publications (1)

Publication Number Publication Date
MX2022012073A true MX2022012073A (es) 2022-10-18

Family

ID=60655897

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018015474A MX2018015474A (es) 2016-06-14 2017-06-14 Metodos para el diagnostico y el tratamiento del cancer metastasico.
MX2022012073A MX2022012073A (es) 2016-06-14 2018-12-13 Metodos para el diagnostico y el tratamiento del cancer metastasico.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2018015474A MX2018015474A (es) 2016-06-14 2017-06-14 Metodos para el diagnostico y el tratamiento del cancer metastasico.

Country Status (8)

Country Link
US (2) US11236331B2 (es)
EP (1) EP3468564A4 (es)
JP (2) JP7306829B2 (es)
CN (1) CN109562121A (es)
AU (1) AU2017285726B2 (es)
CA (2) CA2932910A1 (es)
MX (2) MX2018015474A (es)
WO (1) WO2017214726A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019147822A2 (en) * 2018-01-24 2019-08-01 Northwestern University Inhibiting tumor cell migration by inhibition of kinesin light chain 1, variant 1 (klc1c)
WO2020049139A1 (en) * 2018-09-06 2020-03-12 Scandion Oncology A/S Urea derivatives for use in the treatment of subjects with elevated expression and/or activity of srpk1
CN117187375B (zh) * 2023-09-12 2024-06-18 上海谱希和光基因科技有限公司 Kdelr3生物标志物在诊断高度近视中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US6040166A (en) 1985-03-28 2000-03-21 Roche Molecular Systems, Inc. Kits for amplifying and detecting nucleic acid sequences, including a probe
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
CA1340807C (en) 1988-02-24 1999-11-02 Lawrence T. Malek Nucleic acid amplification process
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
DE3938907C2 (de) 1989-11-24 1999-11-04 Dade Behring Marburg Gmbh Mittel zum Lagern und Suspendieren von Zellen, insbesondere Erythrozyten
FR2814349B1 (fr) 2000-09-27 2002-12-06 Salomon Sa Sac a dos
CA2621070A1 (en) * 2005-09-02 2007-03-08 Toray Industries, Inc. Composition and method for diagnosing kidney cancer and estimating kidney cancer patient's prognosis
CN101300348A (zh) 2005-09-02 2008-11-05 东丽株式会社 肾癌诊断、肾癌患者预后预测用的组合物及方法
WO2007056604A2 (en) 2005-11-09 2007-05-18 Irm Llc Methods and compositions for modulating cell motility and inhibiting tumor metastasis
GB0724532D0 (en) 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
WO2013098797A2 (en) * 2011-12-31 2013-07-04 Kuriakose Moni Abraham Diagnostic tests for predicting prognosis, recurrence, resistance or sensitivity to therapy and metastatic status in cancer
JP6663149B2 (ja) 2014-07-04 2020-03-11 国立大学法人高知大学 膵がん細胞浸潤転移阻害剤

Also Published As

Publication number Publication date
JP7306829B2 (ja) 2023-07-11
AU2017285726A1 (en) 2019-01-24
EP3468564A1 (en) 2019-04-17
CA3027430A1 (en) 2017-12-21
CN109562121A (zh) 2019-04-02
US20190177727A1 (en) 2019-06-13
EP3468564A4 (en) 2020-07-29
JP2023123748A (ja) 2023-09-05
WO2017214726A1 (en) 2017-12-21
AU2017285726B2 (en) 2023-03-16
CA2932910A1 (en) 2017-12-14
MX2018015474A (es) 2019-06-06
US11236331B2 (en) 2022-02-01
AU2023203737A1 (en) 2023-07-06
JP2019525903A (ja) 2019-09-12
US20220112498A1 (en) 2022-04-14

Similar Documents

Publication Publication Date Title
NZ741324A (en) Anti-cd47 antibodies and methods of use
PH12017501967A1 (en) Maize plant dbn9936 and method for use in detecting nucleic acid sequence thereof
SG10201906513WA (en) Crispr hybrid dna/rna polynucleotides and methods of use
MX2020008976A (es) Biomarcadores y su uso en el tratamiento de condiciones relacionadas con pd-1 y pd-l1.
MX2022012073A (es) Metodos para el diagnostico y el tratamiento del cancer metastasico.
WO2017127731A8 (en) Nmr methods and systems for the rapid detection of bacteria
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
NZ629555A (en) Monocyte biomarkers for cancer detection
EP3361251A4 (en) METHOD FOR DETECTION OF CANCER CELLS, REAGENT FOR INTRODUCING SUBSTANCE IN CANCER CELLS, AND COMPOSITION FOR TREATING CANCER
IL245623B (en) System and method for detecting forgeries
PH12017501957A1 (en) Herbicide-tolerant maize plant dbn9858, and nucleotide sequence and method for detecting same
WO2014205266A3 (en) Compositions and methods for detecting and treating glioblastoma
MX2018015213A (es) Secuencia de acido nucleico para detectar la existencia del evento de soya transgenica dbn9004 en una muestra biologica, equipo que contiene la misma y metodo de deteccion para la misma.
BR112014026440A8 (pt) análises, métodos e aparelhos para avaliação de disrupção de rna.
MX2019002929A (es) Biomarcadores de arn para angioedema hereditario.
NZ730124A (en) A method of predicting risk of recurrence of cancer
GB201804709D0 (en) Method for the cytometric analysis or cell samples
EP3491288A4 (en) BAR COLLIMATOR, BACKLIGHT SYSTEM AND METHOD
HK1255868A1 (zh) 加熱室、加熱爐、分析裝置以及分析樣品中雜質含量的方法
Genaro-Mattos et al. Correction: Antioxidant Activity of Caffeic Acid against Iron-Induced Free Radical Generation—A Chemical Approach
GB201507358D0 (en) System and method for identifying a sample container, a reagent container or a rack
MX2019004219A (es) Metodo para la deteccion de la apolipoproteina e4.
EP3644285A4 (en) MONEY PROCESSING SYSTEM, MONEY PROCESSING MACHINE, CURRENCY AND MONEY PROCESSING PROCESS
EP3128708A4 (en) Method for performing pairing in access network having g.hn technology applied thereto, and access network line concentration instrument (gam), access network terminal (gnt) and access network system using same
EP3918376C0 (de) System, verfahren und verarbeitungsmodul zum detektieren von ein oder mehreren objekten im meeresboden